Drug Database
AM

amphotericin B (Ampholip)

✓ Approved

Bharat Serums and Vaccines Limited · Small Molecule · Small Molecule

What is amphotericin B?

amphotericin B is a small molecule developed by Bharat Serums and Vaccines Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAmpholip
CompanyBharat Serums and Vaccines Limited
Drug ClassSmall Molecule
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Bharat Serums and Vaccines Limited

Therapeutic Indications

amphotericin B is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Cardiac disordersEndocardial disease✓ Approved
Infections and infestationsCandida infection✓ Approved
Infections and infestationsAspergillus infection✓ Approved

Related Research Articles

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

CD9+ B Cells Induce T Follicular Helper Cell Apoptosis to Regulate Germinal Center Regression.

Liao Wenjing W, Song Lijuan L, Xu Meiqian M, Liang Tianhao T et al.

Adenoid hypertrophy (AH) is associated with excessive proliferation of germinal center B (GC-B) cells, yet the mechanisms underlying GC regression and termination remain poorly understood. This study used single-cell RNA sequencing (scRNA-seq) to profile the cellular composition of GC-B cells in AH. A unique subset of GC-B cells expressing CD9 was identified through comprehensive scRNA-seq, flow cytometry, and Mass cytometry (CyToF) analyses, with subsequent studies assessing the roles of CD9 and FOXP1 in GC-B cell differentiation and apoptosis pathways. CD9+ B cells were detected throughout GC-B cell development and were regulated by FOXP1. These cells also exhibited activation of cell death-related pathways, particularly during adenoid development. AH samples showed an increase in T follicular helper (Tfh) cells, accompanied by a reduction in CD9+ B cells. In Cd9 knockout mice, CD9 deficiency led to a significant decrease in serum IgG levels. Further analysis revealed that CD9+ B cells promoted Tfh cell apoptosis via pathways such as ALCAM-CD6. CD9+ B cells may regulate GC-B cell regression by inducing Tfh cell apoptosis, and FOXP1 may play a role in their differentiation. These findings clarify mechanisms of GC degeneration and termination, offering potential targets for AH treatment.

PMID 42669617
Read full article →
PubMedNational science review2026-08-30

Tetraboron MR framework with ortho-B-π-B pattern enables high-efficiency yellow narrowband OLEDs.

Zhang Shuqi S, Yang Yongliu Y, Cheng Zhangli Z, Zhang Tongyuan T et al.

Multiple resonance (MR) frameworks with ortho-boron-π-boron (B-π-B) patterns are promising alternatives to those with para-B-π-B ones for realizing bathochromic narrowband emission, but such cases have been rarely reported, and suffer from significant synthetic challenges. Here, a novel tetraboron MR framework ICZ4B incorporating an ortho-B-π-B pattern was constructed by using indolo[2,3-c]carbazole as the central building block. The well-defined borylation active sites facilitate an efficient one-shot quadruple borylation. ICZ4B not only exhibits bright yellow emission with a small full width at half maximum of 24 nm, but also achieves an improved reverse intersystem crossing rate of 4.7 × 104 s-1. The non-sensitized device realizes an outstanding external quantum efficiency of 36.5%, representing one of the highest results at long wavelengths. This study not only presents a feasible pathway for realizing MR frameworks with ortho-B-π-B patterns via delicate selection of key precursors, but also offers insights for optimizing synthetic strategies for complex MR frameworks.

PMID 42668809
Read full article →
PubMedInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026-08-30

Type 2 Diabetes Reshapes the B-Cell Compartment in Tuberculosis, with Reduction of Transitional B Cells and Expansion of Plasmablasts.

Petrone Linda L, Najafi-Fard Saeid S, Altera Anna Maria Gerarda AMG, Aiello Alessandra A et al.

Type 2 diabetes (T2D) increases the risk of tuberculosis (TB) and TB severity; however, its effects on B-cells in the TB-T2D syndemic are not fully understood. We evaluated by flow cytometry, the distribution of circulating B-cell subsets in patients with TB disease, TB-T2D, subjects with TB infection (TBI), TBI-T2D, healthy controls (HCs), T2D, patients with pulmonary respiratory diseases other than TB (ORDs), and ORD-T2D. Plasma levels of unspecific or PPD-specific IgG and B-cell-related soluble factors were measured by multiplex assays. Total B-cell frequency was similar across groups. TB-T2D patients showed decreased transitional B cells compared to TB, TBI-T2D, HC, and T2D. Transitional B-cell frequency significantly and negatively correlated with HbA1c levels in the TB-T2D group. Moreover, plasmablast frequency was increased in TB-T2D compared to TB, TBI-T2D, and T2D. Unspecific or PPD-specific IgG levels were not modulated by T2D. BAFF levels increased in TB and TB-T2D compared to the other groups, whereas the levels of SDF-1 were decreased in TB and TBI irrespective of T2D, compared to the controls. Overall, T2D reshapes B-cell compartments in TB, reducing potentially anti-inflammatory transitional B-cells and increasing plasmablasts, possibly reinforcing inflammation and impacting B-cell development and humoral immunity in TB-T2D.

PMID 42669362
Read full article →
PubMedBiochimica et biophysica acta. Molecular basis of disease2026-08-30

Targeting CARM1 impairs DNA damage repair and attenuates B-cell acute lymphoblastic leukemia progression.

Liao Peiyun P, Qiu Yingqi Y, Li Meifang M, Hu Rong R et al.

B-cell acute lymphoblastic leukemia (B-ALL) is a prevalent hematological malignancy, posing difficulties in identifying efficacious treatment strategies for refractory and recurrent patients. Our research revealed that coactivator-associated arginine methyltransferase 1 (CARM1) was highly expressed in B-ALL and associated with unfavorable prognostic outcomes. Down-regulation and inhibition of CARM1 effectively suppressed proliferation and colony formation of B-ALL, while also inducing apoptosis and cell cycle arrest. Mechanistically, inhibition or down-regulation of CARM1 reduced PARP1 level and contributed to double-strand breaks (DSBs) accumulation. Inhibition of CARM1 and PARP1 synergistically supressed B-ALL development. Significantly, the inhibition of CARM1 was found to promote memory differentiation and reduce the exhaustion of CD19-CAR-T cells. Taken together, CARM1 inhibition not only suppressed B-ALL but also enhanced the durability of CAR-T cells against B-ALL, which provides novel insights into the tumor suppression and immune regulation of CARM1 inhibition on cancer therapy.

PMID 42669369
Read full article →
PubMedThe American journal of the medical sciences2026-08-30

The Evolving Burden of Hepatitis B and C: Past Trends and Future Projections from the Global Burden of Disease Study 2021.

Chen Yue Y, Mao He-Hui HH, Zhang Ming-Jing MJ, Zhang Jin-Yan JY et al.

Hepatitis B and C continue to pose significant challenges to global public health, and this study is aimed at evaluating their burden. Leveraging data from the Global Burden of Disease 2021, we analyzed age-standardized mortality rates (ASMRs) and age-standardized disability-adjusted life year rates (ASDRs) for hepatitis B and C from 1990 to 2021 using Joinpoint regression, age-period-cohort models, and decomposition analysis. Bayesian age-period-cohort models were applied to project future trends up to 2036. Additionally, we assessed the burden attributable to modifiable risk factors and its association with socioeconomic indicators. From 1990 to 2021, the global ASMR for hepatitis B declined from 12.19 to 7.57 per 100,000, and the ASMR for hepatitis C decreased from 8.18 to 6.10 per 100,000. Despite these decreases, the absolute numbers of deaths and DALYs continued to increase, mainly driven by population growth and aging. In 2021, males carried a disproportionately higher burden of hepatitis B and C compared to females. Moreover, countries with low socioeconomic development faced a greater burden. Notably, high alcohol consumption accounted for 16.20% of hepatitis B DALYs, while drug use was responsible for 49.49% of hepatitis C DALYs. By 2036, ASMRs are projected to decline further to 5.90 per 100,000 for hepatitis B and 5.23 per 100,000 for hepatitis C. Although ASMRs and ASDRs have declined, the global burden of hepatitis B and C remains considerable. Continued efforts in vaccination, antiviral treatment, and control of key risk factors are crucial, especially in populations with a high burden.

PMID 42669393
Read full article →
PubMedThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2026-08-30

Tackling Drug Resistance and Virulence in Proteus mirabilis Infections: Evaluating Rosemary Extract as a Complementary Therapeutic Agent.

Mirzaei Arezoo A, Wagemans Jeroen J, Moghim Sharareh S

The rising antimicrobial resistance in Proteus mirabilis, a primary contributor to catheter-associated urinary tract infections, underscores the urgent need to explore alternative therapeutic approaches. In this study, we evaluated the antibacterial and antivirulence potential of Rosmarinus officinalis L. extract (ROE) against P. mirabilis and concurrently assessed clinical isolates for the presence of key resistance and virulence genes. Forty multi-drug-resistant (MDR) P. mirabilis isolates were analyzed using multiplex PCR to detect carbapenemase genes (b l a NDM, b l a OXA family, b l a SIM-1, b l a VIM-1) and uniplex PCR to identify virulence determinants (mrpA, pmfA, rsbA, rsmA, luxS). ROE was extracted and analyzed using high-performance liquid chromatography (HPLC). The antibacterial, antibiofilm, and antiswarming effects of the extract were assessed. All isolates carried all five virulence genes. Carbapenemase gene profiling revealed b l a VIM-1in 20% of isolates, while b l a OXA-23, b l a OXA-24, and b l a OXA-58 were detected in 10%, 2.5%, and 2.5% of isolates, respectively. Neither b l a SIM-1 nor b l a NDM was identified. HPLC analysis of ROE identified rosmarinic acid as the predominant compound. Although the agar well diffusion assay indicated no bactericidal activity, the broth microdilution method determined a minimum inhibitory concentration (MIC) of 8 mg/mL for both reference and MDR strains. At sub-MIC levels, ROE significantly inhibited swarming motility (up to 86% at 250 μg/mL) and biofilm formation (up to 78% in the reference strain and 76% in MDR isolates at 15.6 μg/mL) in a dose-dependent manner. Notably, biofilm eradication activity was observed only against preformed biofilms of the reference strain, achieving up to 53% reduction. MTT cytotoxicity assays confirmed that ROE in low concentrations (1000-15.6 μg/mL) was nontoxic to Vero cells. These results highlight the concerning prevalence of carbapenemase genes among clinical P. mirabilis isolates and identify ROE as a promising, nontoxic candidate for targeting motility and biofilm formation. These findings suggest ROE may offer a viable strategy for managing drug-resistant P. mirabilis infections.

PMID 42668901
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about amphotericin B